|
Lung Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
We demonstrate that IKKα signaling promotes increased cell malignancy of NSCLC cells as well as lung tumor progression and metastasis in either subcellular localization, through activation of common protumoral proteins, such as Erk, p38 and mTor.
|
30867890 |
2019 |
|
Lung Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
By the nanoimmunoassay (NIA), KRAS is found to activate the protein ERK2, whereas ERK1 activation is found in non-KRAS-associated human lung tumors.
|
28400509 |
2017 |
|
Lung Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Hypoxia-inducible factor-1α, pro-angiogenic protein matrix metalloproteinase 1, and VEGF are all highly expressed in Cr(VI)-transformed cells, in lung tissue from animals exposed to Cr(VI), and in lung tumor tissue from a non-smoking worker occupationally exposed to Cr(VI) for 19 years. p38 MAPK is also activated in Cr(VI)-transformed cells and in human lung tumor tissue.
|
27226640 |
2016 |
|
Lung Neoplasms
|
0.400 |
PosttranslationalModification
|
group |
BEFREE |
In order to investigate the involvement of the IER3/PP2A-B56γ/ERK-positive feedback loop, which leads to sustained phosphorylation/activation of ERK in carcinogenesis, we immunohistochemically examined the expression of IER3 and phosphorylated ERK in lung tumor tissues.
|
26986830 |
2016 |
|
Lung Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Furthermore, both Kras-driven mouse lung tumors and orthotopically grown primary human lung cancers show a significant sensitivity to both a chemical p38 inhibitor and an over-the-counter inhibitor of hyaluronan synthesis.
|
28007785 |
2016 |
|
Lung Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
In line with the isoform-specific requirement of ERK2 for HGF-mediated migration in lung tumour cell models, ERK2 but not ERK1 is shown to be responsible for paxillin serine 126 phosphorylation and its increased turnover at focal adhesions.
|
23549785 |
2013 |
|
Lung Neoplasms
|
0.400 |
Biomarker
|
group |
LHGDN |
Effects of GM-CSF and M-CSF on tumor progression of lung cancer: roles of MEK1/ERK and AKT/PKB pathways.
|
16820947 |
2006 |
|
Lung Neoplasms
|
0.400 |
AlteredExpression
|
group |
LHGDN |
ERK1/2 is activated in non-small-cell lung cancer and associated with advanced tumours.
|
14997206 |
2004 |
|
Lung Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Examination of signaling molecules downstream of the IGF-IR showed the activation of either the Erk1/Erk2 or p38 MAPK pathways, but not both, within the lung tumors.
|
12584565 |
2003 |
|
Lung Neoplasms
|
0.400 |
Biomarker
|
group |
CTD_human |
Map kinase activation correlates with K-ras mutation and loss of heterozygosity on chromosome 6 in alveolar bronchiolar carcinomas from B6C3F1 mice exposed to vanadium pentoxide for 2 years.
|
12376484 |
2002 |
|
Lung Neoplasms
|
0.400 |
Biomarker
|
group |
CTD_human |
Decrease in K-ras p21 and increase in Raf1 and activated Erk 1 and 2 in murine lung tumors initiated by N-nitrosodimethylamine and promoted by 2,3,7,8-tetrachlorodibenzo-p-dioxin.
|
11884234 |
2002 |
|
Lung Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
We examined lung tumors 1-7 mm in largest dimension initiated in male Swiss mice by N-nitrosodimethylamine for pathologic type, Ki-ras mutations and levels of total Ki-ras p21, Ki-ras p21 bound to GTP, raf-1, Erk1 and Erk2 and their phosphorylated (activated) forms, and proliferating cell nuclear antigen.
|
10942532 |
2000 |